Cystic Fibrosis Medication for Gating Mutations

Trial Objective

Cystic Fibrosis Medication for Gating MutationsThis study is evaluating the safety and effectiveness of a new investigational medication called VX-561, an altered form of KALYDECO® (generic: ivacaftor), compared to the original ivacaftor. Researchers believe VX-561 has a longer action time in the blood and may be more stable in the body than ivacaftor. They are testing four different doses of VX-561 to see which dose is as effective as ivacaftor when taken once daily.


New enrollment for this trial is temporarily paused

Who Can Participate

Adults with cystic fibrosis (CF) who are currently taking KAYLDECO (ivacaftor) and have CF gating mutations.

Age: 18+    Gender: Any Gender

Estimated Time Commitment

8 visits up to 20 weeks

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Alexandra Wilson

Alexandra Wilson

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Vertex Pharmaceuticals Incorporated

Principal Investigators

Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at